General (136) Partnerships (27) New Products (8) Acquisitions (6) Financials (2) New Technologies (1)
Pharma and Biotech (152) Corporate (13) Bioscience (8)
2020 (25) 2019 (32) 2018 (25) 2017 (23) 2016 (28) 2015 (12) 2014 (7)
Showing 1‐20 of 152
results per page
21 Sep 2020
Lonza Announces Scientific Advisory Board to Further Strengthen Drug Discovery Solutions & Services
Lonza has announced the formation of a new Scientific Advisory Board to advance in vitro ADME-Tox programs within its Bioscience Business UnitThe...
17 Sep 2020
LamKap Bio Group and Lonza Collaborate to Manufacture Bispecific Antibodies for Cancer Treatment
LamKap Bio Group develops fully human bispecific κλ antibodies targeting malignant cells in solid cancersLonza to provide cell line development,...
15 Sep 2020
Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab
Collaboration to expand lenzilumab manufacturing capacity in advance of potential Emergency Use Authorization in 2020Commercial manufacturing to...
08 Sep 2020
Sheba Medical Center Treats First Patient with CAR-T Cell Immunotherapy Manufactured Using the Lonza Cocoon® Platform
First cancer patient dosed at Sheba Medical Center, Isreal with autologous CAR-T therapy manufactured using Lonza’s Cocoon® PlatformIsraeli...
27 Aug 2020
Lonza Prices CHF 150 Million Straight-Bond with a 0.350% Coupon
20 Aug 2020
IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing
Lonza to utilize of IsoPlexis' IsoLight® automated proteomics platformIsoLight® to be used for functional quality analytics for cell therapy...
04 Aug 2020
Lonza Expands Microbial Capacity and Extends Long-term Partnership with Servier for L-asparaginase API Manufacturing
New mid-scale microbial facility to support Servier with active pharmaceutical ingredient (API) for acute lymphoblastic leukemia (ALL)...
27 Jul 2020
Lonza's Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301 - an Antibody Biopolymer Conjugate for Retinal Diseases
•  Purpose-built bioconjugation facility in Lonza’s Ibex™ Dedicate Biopark to support the potential commercial launch of Kodiak's leading...
13 Jul 2020
Junshi Biosciences and Lonza Partner to Produce a Neutralizing Antibody Tackling COVID-19
Junshi Biosciences developing therapies for COVID-19 in collaboration with a number of global partnersJunshi Biosciences' first SARS-CoV-2...
08 Jul 2020
Lonza Establishes Center of Excellence for Integrated Dry Powder Inhaler Product Development Services
Lonza establishes a new Center of Excellence to leverage its core particle engineering expertise utilizing both particle size reduction and spray...
01 Jul 2020
Lonza Expands Particle Engineering Services
Lonza doubles the network jet-milling capacity for supporting development stage projects and expands the capabilities in specialized cGMP...
18 Jun 2020
Lonza’s New GSv9 TM Media and Feeds Maximize Yield and Batch-to-Batch Consistency to Support Recombinant Protein Production Scale-Up
GSv9™ is Lonza’s newly launched chemically defined media and feeds platform, specifically developed to enhance the performance of the GS Gene...
11 Jun 2020
Anthos Therapeutics Partners with Lonza to Develop and Manufacture Abelacimab (MAA868), a Unique Dual Factor XI / XIa inhibitor
The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved...
10 Jun 2020
Lonza and CELLINK Join Forces to Offer Complete 3D Cell Culture Workflows
Lonza has collaborated with CELLINK to offer a comprehensive 3-dimensional (3D) bioprinting solution designed to advance complete 3D cell culture...
29 May 2020
Surrozen and Lonza Announce Partnership for the Development and Manufacture of Surrozen’s Novel Wnt Activating Antibodies
Surrozen is developing first-in-class bi-specific antibodies that selectively stimulate tissue regenerationLonza to provide cell line development,...
18 May 2020
Moncef Slaoui to Step Down as Member of the Board of Directors of Lonza Group
Basel, Switzerland, 18 May 2020 – Dr Moncef Slaoui has decided to step down from his position as a member of the Lonza Group Board of Directors,...
12 May 2020
Noga Therapeutics and Lonza Announce Collaboration to Develop Autologous Lentiviral Gene Therapy on the Cocoon Platform
Collaboration between Noga Therapeutics and Lonza will leverage the innovative Cocoon® Platform for a novel primary immunodeficiency (PID)...
01 May 2020
Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
•  Collaboration goal to enable manufacturing of up to 1 billion doses per year•  Technology transfer expected to begin in June 2020•  First...
23 Mar 2020
Lonza Launches New TheraPEAK™ SfAAV™ Medium to Boost and Optimize the Production of AAV in Sf9 Insect Cells
Lonza has launched a new medium to enhance and accelerate the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect...
20 Mar 2020
Lonza Joins the MIT Industrial Liaison Program
Lonza joins the MIT Industrial Liaison Program (ILP), gaining access to a vibrant ecosystem of research and technology development.Lonza’s...
1 2 3 4 ... 8 >